Bain Capital Life Sciences Investors as of Dec. 31, 2020
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 26 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 33.2 | $528M | 7.3M | 72.52 | |
| Atea Pharmaceuticals (AVIR) | 14.7 | $235M | 5.6M | 41.78 | |
| Arcutis Biotherapeutics (ARQT) | 7.0 | $112M | 4.0M | 28.13 | |
| Mersana Therapeutics | 5.8 | $92M | 3.4M | 26.61 | |
| Annexon (ANNX) | 5.1 | $81M | 3.2M | 25.03 | |
| Dicerna Pharmaceuticals | 4.3 | $68M | 3.1M | 22.03 | |
| Syros Pharmaceuticals | 3.9 | $63M | 5.8M | 10.85 | |
| C4 Therapeutics Com Stk (CCCC) | 3.4 | $54M | 1.6M | 33.13 | |
| Solid Biosciences | 3.4 | $54M | 7.1M | 7.58 | |
| Dynavax Technologies Corp option | 3.0 | $49M | 11M | 4.45 | |
| Nurix Therapeutics (NRIX) | 2.7 | $42M | 1.3M | 32.88 | |
| Constellation Pharmceticls I | 2.5 | $40M | 1.4M | 28.80 | |
| Aptinyx | 1.9 | $31M | 8.9M | 3.46 | |
| Kymera Therapeutics (KYMR) | 1.9 | $30M | 480k | 62.00 | |
| Aeglea Biotherapeutics | 1.3 | $21M | 2.7M | 7.87 | |
| Marinus Pharmaceuticals | 1.1 | $18M | 1.4M | 12.20 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.9 | $15M | 1.1M | 14.11 | |
| Therapeutics Acquisition Cor Com Cl A | 0.9 | $14M | 1.0M | 13.92 | |
| Arya Sciences Acquisition Corp Iii Com Cl A | 0.7 | $11M | 1.0M | 10.85 | |
| X4 Pharmaceuticals | 0.7 | $11M | 1.6M | 6.43 | |
| Savara (SVRA) | 0.4 | $5.9M | 5.1M | 1.15 | |
| Bctg Acquisition Corp | 0.4 | $5.7M | 500k | 11.44 | |
| Bcls Acquisition Corp Com Cl A | 0.3 | $5.4M | 488k | 11.14 | |
| Frazier Lifesciences Acquisition Corp Unit 12/09/2025 | 0.2 | $3.1M | 300k | 10.38 | |
| Jiya Acquisition Corp Com Cl A | 0.2 | $3.1M | 300k | 10.30 | |
| Helix Acquisition Corp Com Cl A | 0.2 | $2.8M | 250k | 11.37 |
